Characteristics and survival associated with ovarian cancer diagnosed as first cancer and ovarian cancer diagnosed subsequent to a previous cancer

Cancer Epidemiology

Volumn 35, Issue 2, 2011, Pages 112-119

  Berkowitz, Zahava ^a   Rim, Sun Hee ^a   Peipins, Lucy A ^a  

^a NATIONAL CENTER FOR CHRONIC DISEASE PREVENTION AND HEALTH PROMOTION   (United States)

Author keywords

Gynecological cancer; Histology; Ovarian; SEER; Survival

Indexed keywords

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BLADDER CANCER; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER REGISTRY; CANCER RISK; CANCER SURVIVAL; COLON CANCER; ENDOMETRIOID CARCINOMA; FEMALE; HUMAN; LEUKEMIA; MAJOR CLINICAL STUDY; MELANOMA; MUCINOUS CARCINOMA; MYELOMA; OVARY CANCER; OVERALL SURVIVAL; PRIMARY TUMOR; PRIORITY JOURNAL; UTERINE CERVIX CANCER; UTERUS CANCER;

COHORT STUDIES; FEMALE; HUMANS; MIDDLE AGED; NEOPLASMS, SECOND PRIMARY; OVARIAN NEOPLASMS; SEER PROGRAM; SURVIVAL ANALYSIS; UNITED STATES;

EID: 79953116690     PISSN: 18777821     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canep.2010.07.001     Document Type: Article

References (45)

1. Ryerson A.B., Eheman C., Burton J., McCall N., Blackman D., Subramanian S., et al. Symptoms, diagnoses, and time to key diagnostic procedures among older U.S. women with ovarian cancer. Obstet Gynecol 2007, 109(5):1053-1061.
2. U.S. Cancer Statistics Working Group. United States cancer statistics: 1999-2005 incidence and mortality web-based report. Atlanta, GA: Department of Health and Human Services, Center for Disease Control and Prevention; Washington, DC: National Cancer Institute; 2009. Available at: http://www.cdc.gov/uscs.
3. Jemal A., Siegel R., Ward E., Murray T., Xu J., Thun M. Cancer statistics, 2007. CA Cancer J Clin 2007, 57(1):43-66.
4. Chan J.K., Cheung M., Husain A., Teng N.N., West D., Whittemore A.S., et al. Patterns and progress in ovarian cancer over 14 years. Obstet Gynecol 2006, 108(3 Pt 1):521-528.
5. Hankinson S., Danforth K. Ovarian cancer. Cancer epidemiology and prevention 2007, 1013-1026. Oxford University Press, New York. 3rd ed. D. Schottenfeld, J. Fraumeni (Eds.).
6. Modugno F., Ness R., Wheeler J. Reproductive risk factors for epithelial ovarian cancer according to histologic type and invasiveness. Ann Epidemiol 2001, 11(8):568-574.
7. Kurian A.W., Balise R., McGuire V., Whittemore A. Histologic types of epithelial ovarian cancer: have they different risk factors?. Gynecol Oncol 2005, 96(2):520-530.
8. Tung K.H., Goodman M.T., Wu A.H., McDuffie K., Wilkens A.R., Kolonel L.M., et al. Reproductive factors and epithelial ovarian cancer risk by histologic type: a multiethnic case-control study. Am J Epidemiol 2003, 158(7):629-638.
9. Bermejo J., Rawal R., Hemminki K. Familial association of specific histologic types of ovarian malignancy with other malignancies. Cancer 2004, 100(7):1507-1514.
10. Kirova Y.M., De Rycke Y., Gambotti L., Pierga J.Y., Asselain B., Fourquet A. Second malignancies after breast cancer: the impact of different treatment modalities. Br J Cancer 2008, 98(5):870-874.
11. Soerjomataram I., Louwman W., Lemmens V., de Vries E., Klokman W., Coebergh J. Risks of second primary breast and urogenital cancer following female breast cancer in the south of The Netherlands, 1972-2001. Eur J Cancer 2005, 41(15):2331-2337.
12. Hall H.I., Jamison P., Weir H.K. Second primary ovarian cancer among women diagnosed previously with cancer. Cancer Epidemiol Biomarkers Prev 2001, 10(9):995-999.
13. National Cancer Institute Surveillance Research Program Surveillance epidemiology and end result (SEER) 2007 April, National Cancer Institute, Bethesda, MD, Available at: URL:. http://www.seer.cancer.gov/seerstat.
14. The SEER program code manual. Report No.: 3rd ed. Bethesda, MD: National Cancer Institute; 1998.
15. Curtis R., Ries L. Methods. New malignancies among cancer survivors: SEER cancer registries, 1973-2000. Ref type: serial (book, monograph) 2006, National Cancer Institute, Bethesda, MD, NIH Publ. No. 05-5302 [Chapter 2]. R.E. Curtis, D.M. Freedman, E. Ron, L.A.G. Ries, D.G. Hacker, B.K. Edwards, M.A. Tucker, J.F. Fraumeni (Eds.).
16. Young J.J., Roffers S., Ries L., Fritz A., Hurlbut A. SEER summary staging manual-2000: codes and coding instructions. NIH Pub. No. 01-4969 2001, National Cancer Institute, Bethesda, MD.
17. Allison P.D. Survival analysis using the SAS system. A practical guide 1995, SAS Institute Inc., Cary, NC.
18. Collet D. Modeling survival data in medical research 1994, Chapman & Hall/CRC. 1st ed.
19. Cress R., O'Malley C., Leiserowitz G., Campleman S. Patterns of chemotherapy use for women with ovarian cancer: a population-based study. J Clin Oncol 2003, 21:1530-1535.
20. Ji J., Forsti A., Sundquist J., Lenner P., Hemminki K. Survival in ovarian cancer patients by histology and family history. Acta Oncol 2008, 47:1133-1139.
21. Choi M., Fuller C., Thomas C., Wang S. Conditional survival in ovarian cancer: results from the SEER dataset 1988-2001. Gynecol Oncol 2008, 109(2):203-209.
22. Brun J.L., Feyler A., Chene G., Saurel J., Brun G., Hocke C. Long-term results and prognostic factors in patients with epithelial ovarian cancer. Gynecol Oncol 2000, 78(1):21-27.
23. Ikeda K., Sakai K., Yamamoto R., Hareyama H., Tsumura N., Watari H. Multivariate analysis for prognostic significance of histologic subtype, GST-pi, MDR-1, and p53 in stages II-IV ovarian cancer. Int J Gynecol Cancer 2003, 13(6):776-784.
24. Earle C.C., Schrag D., Neville B.A., Yabroff K.R., Topor M., Fahey A., et al. Effect of surgeon specialty on processes of care and outcomes for ovarian cancer patients. JNCI 2006, 98(3):172-180.
25. Bristow R.E., Montz F.J., Lagasse L.D., Leuchter R.S., Karlan B.Y. Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer. Gynecol Oncol 1999, 72:278-287.
26. Aletti G.D., Dowdy S.C., Gostout B.S., Jones M.B., Stanhope C.R., Wilson T.O., et al. Aggressive surgical effort and improved survival in advanced-stage ovarian cancer. Obstet Gynecol 2006, 107(1):77-85.
27. Lynch H., Lanspa S., Smyrk T., Boman B., Watson P., Lynch J. Hereditary nonpolyposis colorectal cancer (Lynch syndromes I and II): genetics, pathology, natural history, and cancer control, part I. Cancer Genet Cytogenet 1991, 53:143-160.
28. Malander S., Rambech E., Kristoffersson U., Halvarsson B., Ridderheim M., Borg A., et al. The contribution of the hereditary nonpolyposis colorectal cancer syndrome to the development of ovarian cancer. Gynecol Oncol 2006, 101(2):238-243.
29. Newman B., Millikan R., King M. Genetic epidemiology of breast and ovarian cancers. Epidemiol Rev 1997, 19:69-79.
30. Rubin S., Blackwood M., Bandera C., Behbakht K., Benjamin I., Rebbeck T., et al. BRCA1, BRCA2, and hereditary nonpolyposis colorectal cancer gene mutations in an unselected ovarian cancer population: relationship to family history and implications for genetic testing. Am J Obstet Gynecol 1998, 178:670-677.
31. Schottenfeld D., Beebe-Dimmer J. Multiple primary cancers. Cancer epidemiology and prevention 2006, 1269-1280. Oxford University Press Inc., New York. 3rd ed. D. Schottenfeld, J.F. Fraumeni (Eds.).
32. Welcsh P., King M. BRCA1 and BRCA2 and the genetics of breast and ovarian cancer. Hum Mol Genet 2001, 10:701-713.
33. Anderson H., Bladstron A. Familial breast and ovarian cancer: a Swedish population-based register study. Am J Epidemiol 2000, 152(12):1154-1163.
34. Gutman M., Cnaan A. Are malignant melanoma patients at higher risk for a second cancer?. Cancer 1991, 68(3):660-665.
35. Robinson E., Adler A., Nasrallah S., Kuten A., Steiner M., Rennert G., et al. Clinical characteristics of patients with a second primary tumor in the endometrium or ovary. Eur J Gynaecol Oncol 1995, 16:195-198.
36. Cook L., Weiss N., Doherty J., Chen C. Endometrial cancer. Clinical gynecologic oncology 2007, Elsevier Inc., Philadelphia. 7th ed. P. DiSaia, W. Creasman (Eds.).
37. Fathalla M. Incessant ovulation-a factor in ovarian neoplasia?. Lancet 1971, 2:163.
38. Mills P., Riordan D., Cress R., Goldsmith D. Hormone replacement therapy and invasive and borderline epithelial ovarian cancer risk. Cancer Detect Prev 2005, 29:124-132.
39. Riman T., Persson I., Nilsson S. Hormonal aspects of epithelial ovarian cancer: review of epidemiological evidence. Clin Endocrinol 1998, 49:695-707.
40. Rossouw J., Anderson G., Prentice R. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002, 288(3):321-333.
41. Althuis M.D., Scoccia B., Lamb E.J., Moghissi K.S., Westhoff C.L., Mabie J.E., et al. Melanoma, thyroid, cervical, and colon cancer risk after use of fertility drugs. Am J Obstet Gynecol 2005, 193(3 Pt 1):668-674.
42. Lacey J.V., Brinton L., Leitzmann M.F., Mouw T., Hollenbeck A., Schatzkin A., et al. Menopausal hormone therapy and ovarian cancer risk in the National Institutes of Health-AARP Diet and Health Study Cohort. J Natl Cancer Inst 2006, 98(19):1397-1405.
43. Morch L., Lokkegaard E., Andreasen A., Kruger-Kjaer S., Lidegaard O. Hormone therapy and ovarian cancer. JAMA 2009, 302:298-305.
44. Boice J., Engholm G., Kleinerman R. Radiation dose and second cancer risk in patients treated for cancer of the cervix. Radiat Res 1988, 116:3-55.
45. Wingo P.A., Jamison P.M., Hiatt R.A., Weir H.K., Gargiullo P.M., Hutton M., et al. Building the infrastructure for nationwide cancer surveillance and control-a comparison between the National Program of Cancer Registries (NPCR) and the Surveillance, Epidemiology, and End Results (SEER) Program (United States). Cancer Causes Control 2003, 14:175-193.